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Summary
Isovaleric acidemia (IVA) is a recessive disorder caused
by a deficiency of isovaleryl-CoA dehydrogenase (IVD).
We have reported elsewhere nine point mutations in the
IVD gene in fibroblasts of patients with IVA, which lead
to abnormalities in IVD protein processing and activity.
In this report, we describe eight IVD gene mutations
identified in seven IVA patients that result in abnormal
splicing of IVD RNA. Four mutations in the coding re-
gion lead to aberrantly spliced mRNA species in patient
fibroblasts. Three of these are amino acid altering point
mutations, whereas one is a single-base insertion that
leads to a shift in the reading frame of the mRNA. Two
of the coding mutations strengthen pre-existing cryptic
splice acceptors adjacent to the natural splice junctions
and apparently interfere with exon recognition, resulting
in exon skipping. This mechanism for missplicing has
not been reported elsewhere. Four other mutations alter
either the conserved gt or ag dinucleotide splice sites in
the IVD gene. Exon skipping and cryptic splicing were
confirmed by transfection of these mutations into a Cos-
7 cell line model splicing system. Several of themutations
were predicted by individual information analysis to in-
activate or significantly weaken adjacent donor or ac-
ceptor sites. The high frequency of splicing mutations
identified in these patients is unusual, as is the finding
of missplicing associated with missense mutations in ex-
ons. These results may lead to a better understanding
of the phenotypic complexity of IVA, as well as provide
insight into those factors important in defining intron/
exon boundaries in vivo.
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Introduction
Isovaleric acidemia (IVA) (MIM 243500) is an organic
acidemia caused by a deficiency of the enzyme isovaleryl-
CoA dehydrogenase (IVD; E.C.1.3.99.10), which cata-
lyzes the third step in the catabolism of the amino acid
leucine. Deficiency of IVD results in the failure of iso-
valeryl-CoA to be oxidized to 3-methylcrotonyl-CoA
(Sweetman and Williams 1995). It is usually character-
ized by severe, often fatal neonatal ketotic acidosis. Ap-
proximately 50% of patients with this disorder present
in the newborn period with overwhelming acidosis. The
remainder exhibit a less-severe clinical picture charac-
terized by developmental delay or mental retardation,
with or without episodes of intermittent acidosis. Infants
who survive a severe neonatal crisis are subsequently
clinically indistinguishable from patients with the more
chronic form of the disease and continue to show a pat-
tern of chronic intermittent acidotic episodes during in-
tercurrent illnesses or other times of physiological stress.
The mechanism for this clinical variability remains
unclear.
IVD is a mitochondrial flavoenzyme and a member of
the family of acyl-CoA dehydrogenases (ACDs), which
includes short/branched chain acyl-CoA dehydrogenase
(SBCAD), short chain acyl-CoA dehydrogenase (SCAD),
medium chain acyl-CoA dehydrogenase (MCAD), long
chain acyl-CoA dehydrogenase (LCAD), and very long
chain acyl-CoA dehydrogenase (VLCAD) (Ikeda et al.
1986, 1987). These enzymes are encoded in the nuclear
genome in precursor form. Precursor peptides are syn-
thesized in the cytoplasm, transported into mitochon-
dria, and processed to homotetramers (except VLCAD,
which is processed to a homodimer), with eachmonomer
containing a noncovalently but tightly bound flavin ad-
enine dinucleotide molecule (Ikeda et al. 1986, 1987).
All ACDs catalyze the a,b-dehydrogenation of their cor-
responding acyl-CoA thio-ester substrates, with each
ACD having a distinct substrate specificity profile and
all transfer electrons to the electron-transferring flavo-
protein (ETF) (Crane and Beinert 1955; Ikeda et al.
1983, 1985a, 1985c).
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[35S]methionine–protein-labeling studies of fibroblasts
from IVA patients have revealed at least five classes of
mutations within the IVD gene (Ikeda et al. 1985a). IVD
precursor and mature proteins produced by type I mu-
tants are indistinguishable in size from their normal
counterparts. Types II, III, and IV mutants make IVD
precursor proteins, which are 2–3 kDa smaller than nor-
mal. Subsequent processing in type III and IV mutants
is normal but proceeds inefficiently in type II mutants.
Type V mutants make no detectable IVD protein. We
have elsewhere described nine point mutations in the
IVD gene in fibroblasts from patients with IVA, which
lead to Leu13Pro, Arg21Pro, Asp40Asn, Gly170Val,
Ala282Val, Cys328Arg, Val342Ala, Arg363Cys, and
Arg382Leu replacements in IVD protein (Vockley et al.
1991, 1992a, 1992b; Mohsen et al. 1998). The mutant
enzymes exhibit decreased intramitochondrial stability
and enzymatic activity. In other IVA cell lines, IVD
mRNA is abnormal or absent, but a causative mutation
could not be identified (Vockley et al. 1991, 1992a). We
now report IVD gene mutations in IVA patients, which
lead to abnormal processing of IVD RNA.
Material and Methods
Cell Lines and Mutation Detection
Fibroblast cell lines were obtained through contact
with referring physicians who requested enzymatic test-
ing for isovaleric acidemia. Approval for these studies
was obtained through the Mayo Foundation Institu-
tional Review Board. Cells were cultured in DMEMme-
dia (GibcoBRL Life Technologies), supplemented with
10% fetal calf serum. IVD activity in fibroblast extracts
was measured by means of the electron transferring fla-
voprotein fluorescence reduction assay, as described else-
where (Vockley et al. 1991; Mohsen et al. 1998). Point
mutations in FB102, FB103, and FB834 have been de-
scribed elsewhere (Vockley et al. 1991; Mohsen et al.
1998). Genomic DNA was isolated by means of the Pur-
egene Kit, according to the manufacturer’s protocol
(Gentra Systems). mRNA was isolated from confluent
fibroblast cultures by means of the QuickPrep kit, ac-
cording to the manufacturer’s instructions (Pharmacia
Biotech). cDNA was synthesized by use of the SUPER-
SCRIPT Preamplification System, for first-strand cDNA
synthesis (GibcoBRL Life Technologies). Mutations in
the IVD gene were identified in genomic DNA and
cDNA, made from mRNA from cell lines, as described
elsewhere (Vockley et al. 1991; Mohsen et al. 1998). All
exons and intron/exon boundaries were amplified from
genomic DNA, and cDNA was amplified in overlapping
fragments through the polymerase chain reaction (Vock-
ley et al. 1991; Parimoo and Tanaka 1993; Mohsen et
al. 1998). PCR-amplified products were subcloned into
PCRScript (Stratagene), and at least six subclones were
sequenced either manually, with the 7-deaza-dGTP Se-
quenase V2.0 kit (Amersham), or in automated fashion,
by the Mayo Clinic Molecular Biology Core Facility.
Alternatively, amplification products were sequenced di-
rectly by the Mayo Clinic Molecular Biology Core Fa-
cility after purification via a Qiaquick PCR purification
kit (Qiagen), according to the manufacturer’s instruc-
tions.
Evaluation of Splicing Mutations by Use of an Exon-
Trapping System
Cos-7 (1651-CRL) cells were obtained fromAmerican
Type Culture Collection. The exon-trapping system,
with the pSPL3 vector, LipofectACETM reagent, and the
Superscript II kit, was obtained from GibcoBRL Life
Technologies. All other reagents and chemicals, unless
otherwise stated, were from Fisher, Sigma, or GibcoBRL
Life Technologies. PCR products amplified from patient
and control fibroblast genomic DNA were ligated into
T-tailed-EcoRV-digested pSPL3 vector and transformed
into DH5a cells. Amplified regions of IVD were FB103,
FB118, FB136, and FB834, exon 1 to intron 3; FB136,
intron 6 to intron 9. Primers to amplify exon 1 to intron
3 were 5′, nucleotides 103–123 of the coding sequence;
3′, 59–79 bp downstream of the splicing donor site for
intron 3. Primers to amplify intron 6 to intron 9 were
5′, 93–113 nucleotides upstream from the splicing ac-
ceptor site for intron 6; 3′, 56–76 nucleotides down-
stream of the splicing donor site for intron 9. Transfor-
mants containing the desired inserts in the correct
orientation were identified by restriction enzyme analysis
and automated DNA sequencing. About 0.5–1 mg of the
purified plasmid DNA was transfected, along with ap-
propriate control DNAs, into Cos-7 cells by means of
LipofectACETM reagent, according to the manufacturer’s
protocol, and total RNA was isolated 48–72 h after
transfection by means of RNA STAT 60 (Tel-Test). One
microgram of total RNA (in 10-ml volume) was treated
with DNAse I (Boehringer Mannheim) at 37C for 15
min, followed by inactivation at 65C for 15 min. Re-
verse transcription (RT) was done in a total volume of
20 ml by means of the treated RNA and the Superscript
II kit. Five microliters of the RT product were amplified
by use of AmpliTaq DNA polymerase (PE Biosystems),
and the pSPL3-specific primers—SA2 and SD6
(GibcoBRL Life Technologies)—in a total volume of 25
ml in a GeneAmp PCR System 9600 (PE Biosystems), by
means of the following thermal profile: initial denatur-
ation for 5 min at 94C; cycling for 1 min at 94C, for
1 min at 60C, and for 3 min at 72C (35 cycles); and
a final extension step for 10 min at 72C. Fivemicroliters
of the RT-PCR product derived from the respective pa-
tient and control DNAwere separated by electrophoresis
Figure 1 Summary of mutations in the IVD gene leading to abnormal splicing of IVD RNA. IVD sequences, including intron and exon
boundaries, were amplified from genomic DNA isolated from cell lines from patients with IVA and shown to be deficient in IVD enzymatic
activity. Mutations identified are listed. For FB102, the effect of the intron 7 mutation on cDNA sequence is also shown. FB118 and FB145
were homozygous for their respective mutations. Only one mutation could be identified in FB143, despite complete sequencing of all exons
and extensive sequencing of the intron/exon boundaries. The remaining mutation in the IVD gene responsible for this patient’s IVA is unknown.
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on a 1% agarose gel for analysis. Bands from both nor-
mal and mutant samples were excised from the gel and
purified by means of a Qiaquick gel extraction kit (Qia-
gen) and were sequenced by the Mayo Clinic Molecular
Biology Core Facility either directly or after subcloning
into pGEM-T vector (Promega).
Computer Analysis of Splicing Mutations
Genomic sequences spanning an interval of 50 nucle-
otides up- and downstream of each substitution were
evaluated by information analysis of splice donor and
acceptor sites (Rogan et al. 1998). By using the Scan
program (from the Laboratory of Computational and
Experimental Biology at the National Institutes of
Health), we analyzed the individual information content
of each natural and variant primary and secondary splice
site by measuring their Ri value expressed in bits of in-
formation (Schneider 1997a). The programs Make-
Walker and Lister were used to generate graphic displays
of these findings (Rogan et al. 1998). The effects of nu-
cleotide substitutions on splicing information were pre-
dicted from Ri values. The following criteria were val-
idated in a previous study of 111 splice-site variants
(Schneider 1997a, 1997b):
(1) Substitutions resulting in Ri values of !2.4 bits
were predicted to completely inactivate the natural site.
(2) Substitutions with decreased Ri values of 12.4 bits
were predicted to result in leaky splicing. To predict the
residual amount of mRNA correctly spliced at such leaky
sites, we calculated the minimum fold change in binding
affinity as 2DRi (DRi is the difference between the Ri value
of the natural site and that of the variant site); the result
was expressed as the percentage of normally processed
mRNA (Schneider 1997a; Rogan et al. 1998).
(3) Substitutions with secondary or cryptic splice sites
near the primary site with Ri values greater than the
natural splice site were predicted to result in cryptic
splicing.
(4) Nucleotide changes that did not have significant
impact on the DRi of the natural site were predicted not
to affect splice site function (Schneider 1997a, 1997b).
Significance of the change in Ri was assessed by means
of a paired t test, with a cutoff at 5% significance (Rogan
et al. 1998).
Results
We have elsewhere identified nine point mutations in
the IVD gene in fibroblasts from patients with enzy-
matically proved IVD deficiency (Vockley et al. 1991,
1992a, 1992b; Mohsen et al. 1998). In some cell lines,
however, only one IVD coding mutation was found,
whereas in others, multiple aberrant IVD cDNA species
were present. The additional causative mutations in
these cell lines were not identified. To examine these cell
lines for mutations affecting IVD RNA processing, all
exons and intron/exon boundaries of the IVD gene were
amplified by PCR and sequenced from patient genomic
DNA and cDNA. Wild-type IVD intron-exon boundary
sequence information has been deposited in Genbank
(accession numbers AF191214 to AF191218) and is also
available on request. Figure 1 summarizes the sequence
alterations identified in seven IVD-deficient cell lines.
Five missense mutations were identified in cDNA and
were confirmed to be present in genomic DNA (fig. 1–3:
148CrT, 149GrC, 205GrA, 596GrT, and 932CrT).
In addition, a G insertion in exon 8 and four splice-
junction mutations occurring at the conserved gt-or-ag
dinucleotide were found. Of these cell lines, only FB102
shows any residual enzyme activity, and this can be at-
tributed to the partial activity of the mutant 282
AlarVal enzyme (Mohsen et al. 1998). During the past
10 years, we have analyzed 120 cell lines for IVD mu-
tations. Only one (the 148GrC mutation) has ever been
seen in more than one cell line. Thus, the othermutations
have been identified only once in 40 alleles (J. Vockley,
unpublished data, and Vockley et al. 1991, 1992a,
1992b; Mohsen et al. 1998).
Missplicing Caused by Mutations in the IVD Coding
Region
Three of the IVDmissense mutations and the insertion
mutation in exon 8 are associated with exon-skipping.
This rather unexpected finding led us to seek proof that
these mutations were directly responsible for the splicing
abnormalities. We therefore used an exon-trapping vec-
tor-based model RNA splicing system to verify the for-
mation of abnormal mRNA species (Liu et al. 1997).
Results are summarized in figure 4.
Previous analysis of FB834 mRNA suggested that
skipping of exon 2 was occurring in this cell line, but
the cause of this was not determined (Vockley et al.
1991, 1992a). We have now identified a CrT mutation
at position 148, which results in a missense change (21
ArgrCys, fig. 2A). This involves the same codon mu-
tated in FB118 but at a different nucleotide position and
appears to impair splicing to a greater extent than the
149 mutation, since no cDNA containing the point mu-
tation in exon 2 could be amplified from cDNA. Exon-
trapping analysis shows that the 148 mutation indeed
causes skipping of exon 2 (fig. 4A and 4D).
cDNA amplification of DNA flanking exon 2 from
FB118 yielded two products—a 306-bp–sized fragment
and a less abundant species of 216 bp. Sequence analysis
confirms that the larger fragment contains exon 2 with
the coding mutation (149GrC), whereas the smaller is
missing exon 2 (90 bp; fig. 3A). Apparently, the ho-
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Figure 2 Sequencing of DNA fragments amplified from IVD genomic DNA from IVA fibroblasts. A, Direct sequence of amplified genomic
DNA from FB834, showing a 148CrT mutation. The patient is heterozygous at this position. B, 149GrC mutation in FB118 in products
amplified from genomic DNA and sequenced directly. The patient is homozygous for this mutation, which was also identified in FB136. Control
experiments confirmed that this was not related to contamination of PCR reactions with previously amplified template. C, Insertion of a G
residue in genomic DNA from FB136 in an area that normally contains six Gs from cDNA positions 865–870. Direct sequence from amplified
genomic DNA is shown. Because the patient is heterozygous for this mutation, a double sequencing pattern appears after the inserted nucleotide.
This finding was confirmed in the reverse direction and by sequencing of subclones of the PCR amplified genomic DNA from this region (not
shown). D, GrA point mutation of the intron 7 splice acceptor site in FB102 genomic DNA, identified by direct sequencing of amplified DNA.
The patient is heterozygous at this location. The mutant A allele is easily visualized in the forward direction shown, whereas the wild-type G
signal is more evident in the reverse direction (not shown).
mozygous 149GrC mutation (21 ArgrPro) in this pa-
tient leads to missplicing of exon 2. To evaluate this
mutation, a fragment extending from exon 1 to intron
3, containing the mutation, was tested in an exon-trap-
ping assay. Skipping of exon 2 was observed in the frag-
ment containing 149GrC but not in the fragment with
the normal sequence (fig. 4B and 4D).
FB136 harbors coding mutations in both IVD alleles,
one of which has a 149GrC mutation (as in FB118).
Exon 2 was deleted in one of seven subclones of PCR-
amplified cDNA derived from this cell line. As shown
for FB118, this mutation leads to exon 2 skipping. The
other mutation is a single G insertion in exon 8 within
a polyguanine run nine nucleotides upstream from the
donor site (fig. 1 and 2C). Of nine amplified cDNA sub-
clones analyzed from this patient, one contained the in-
serted guanine residue in exon 8, another was missing
exon 8, and six had the normal sequence (fig. 3C and
3D). Mutations were not found in adjacent splice junc-
tions, indicating that the exon skipping is related to this
insertion. Genomic fragments consisting of introns 6–9
were tested with the exon-trapping system (fig. 4E and
4F); bands 6 and 5 correspond to cDNA fragments with
and without exon 8, respectively. Fragments missing
exon 8 were also identified when wild-type sequencewas
present, but insertion of a G at position 870 leads to a
much larger proportion of skipped exon 8 product than
a control (58% vs 10%, by densitometry). Skipping of
exon 8 has never been identified in control cDNAs made
from human fibroblasts or liver (data not shown), and
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Figure 3 Identification of exon skipping in mRNA from IVA fibroblasts. A, Agarose gel of DNA fragments amplified from cDNA from
FB118. The 5′ amplification primer was in the 5′ untranslated region of IVD (position 20 to 1) and the 3′ amplification primer was from
position 265–286, spanning exons 1–3. Arrows mark the predicted size of a normal fragment (306 bp) and one with a deletion of exon 2 (90
bp). The migration positions of 100 bp molecular mass standards are shown. B, Manual DNA sequencing of a subcloned DNA fragment
amplified from FB102 cDNA, including exons 7 and 8. The arrows show the position of the gra mutation in the intron 7 splice acceptor site.
Sequences corresponding to exon 7, intron 7, and exon 8 are marked. C and D, Analysis of subclones of amplified products from FB136 cDNA,
spanning exons 3–11 (5′ primer, IVD coding nucleotides 318–347; 3′ primer, IVD coding nucleotides 1122–1138; anticipated size 820 bp). Two
different-sized inserts are obtained after subcloning, as seen on agarose gel electrophoresis (C). The sequence of the insert from lane 1 is normal
(not shown). The sequence of the insert from lane 2 shows a deletion of exon 8 (D).
thus, the low level of exon 8 skipping seen with wild-
type sequence may be an artifact of the exon-trapping
system.
Several subclones of amplified cDNA from FB103
were missing exon 2, presumably related to the 205GrA
(40 AsprAsn) mutation in this exon reported elsewhere
(Mohsen et al. 1998). This observation was confirmed
with our exon-trapping assay (fig. 4B). When a normal
genomic IVD fragment extending from the middle of
exon 1 to intron 3 is present in the vector, either two
or three products are obtained after amplification of
cDNA from transfected cells (fig. 4B, bands 2 and 3).
Band 2 consists of exons 2 and 3 spliced correctly to the
vector donor and acceptor sites (fig. 4D). Band 3 con-
tains exons 1–3, joined appropriately but with a cryptic
acceptor site in the vector being used. Both bands 2 and
3 are anticipated products of the splicing reaction; be-
cause no acceptor site precedes exon 1, the vector donor
site selects either the nearest acceptor site, in exon 2, or
a cryptic acceptor site in the vector. Heteroduplexes of
these two products are sometimes also detected (band
4). When a similar fragment containing the 205GrA
mutation is used, an additional product that contains
only exon 3 is detected—that is, exons 1 and 2 have
been skipped (band 1). Because skipping of exon 1 is
seen with the wild-type IVD fragment, our results sug-
gest that the 205GrA mutation is responsible for the
skipping of exon 2.
362 Am. J. Hum. Genet. 66:356–367, 2000
Figure 4 Use of an exon-trapping system to examine the effects of IVD exon mutations on RNA splicing. IVD genomic DNA fragments,
containing control or mutation sequences, spanning exon 1 to intron 3 (A–D) or intron 7 to intron 9 (E–F) were cloned into the exon-trapping
vector pSPL3. Inserts for all clones were sequenced to confirm that no PCR errors were present. The vector was transiently transfected into
COS-7 cells, and total RNA from transfected cells was used as template for RT-PCR, with vector-specific primers. Amplified products were
separated by electrophoresis on agarose gels and visualized with ethidium bromide staining. The number of products listed below the vector
maps correspond to the numbering of the bands on the gel photo. Lanes containing PCR products amplified from cDNA of cells transfected
with control and mutant IVD sequences are marked as “C” and “M,” respectively. The mutation being analyzed is listed underneath, and the
migration of molecular mass markers is indicated to the left of each gel photograph. A, 148CrT; B, 149GrC; C, 205GrA. D and F, Map of
amplified products identified by sequencing subcloned products obtained with normal and mutant IVD exon-trapping experiments. The test
IVD exon-trapping vector plus insert is depicted on the top line. IVD exons are shown as white boxes and exon sizes are as labeled. Vector
exon sequences (V) are denoted by black boxes and intron sequences by a line. Donor and acceptor sites are indicated by D and A, respectively.
The horizontal arrows indicate the position of PCR primers. D and F, Exon 2 splicing test vector. Cryptic acceptor site in vector is indicated
by “a.” E, iG870 = insertion of G at position 870 in the IVD coding region. F, Exon 8 splicing test vector.
Mutations in the IVD Gene Splice Junctions
Mutations at the conserved gt-or-ag dinucleotides of
splice junctions were identified in four IVD-deficient cell
lines. These mutations were not tested in an exon-trap-
ping system. IVD mRNA from FB102 contains an in-
sertion of 15 nucleotides from the 3′ end of intron 7 (fig.
1). This missplicing is the result of a gra mutation in
the intron 7 acceptor site, altering the ag acceptor site
to aa (fig. 2D). Consequently, a cryptic splice acceptor
site in intron 7, located 15 nucleotides upstream of exon
8, is used, accounting for the 15-nt insertion in the
cDNA. This insertion maintains the correct reading
frame. FB145 harbors a homozygous intron 4 splicing
donor site trc mutation that alters the conserved gt to
gc. IVD sequences could not be amplified from cDNA
derived from FB145, which suggests that the IVD
mRNA is unstable in this cell line. A grc mutation at
the donor site in intron 4 of the IVD gene in FB103
converts the conserved gt dinucleotide to at. cDNAmiss-
ing exon 4 was identified in a minority of clones made
from amplified cDNA. This patient also had a coding
mutation in the other allele, as described elsewhere
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Table 1
Information Analysis of IVD Gene Mutations
PATIENT
SPLICE JUNCTION
AFFECTED
PRIMARY SPLICE SITE SECONDARY SPLICE SITE
PREDICTED
RESIDUAL
SPLICINGb
(%
NORMAL)
NT
Positiona
Ri, Natural r Ri,
Mutant (bits)
NT
Position
Ri, Natural r Ri,
Mutant (bits)
FB102 Intron 7, acceptor 1, GrA 5.4 r 2.2 15 5.6 r 5.6
FB103 Intron 4, donor 1, GrA 9.2 r 1.9 (0)
FB118, FB136 Intron 1, acceptor 149GrC 8.5 r 8.5 153 7.3 r 9.8
FB136 Intron 8, donor 8 insertion G 9.2 r 9.2  (100)
FB145 Intron 4, donor 2, TrC 11.0 r 3.5 – (.05)
FB834 Intron 1, acceptor 148CrT 8.5 r 8.5 153 7.3 r 7.5
FB143 Intron 4, acceptor 2, ArG 7.9 r .3 (0)
a Mutation position for coding mutations is listed in terms of the cDNA position. Noncoding mutations are referenced
to the nearest exon/intron junction (a minus sign [] indicates distance from a natural acceptor site, and a plus sign []
indicates distance from a natural donor site; see fig. 1).
b Nucleotide substitutions may result either in a complete loss of primary site function () or in leaky splicing (). Ri-
based predictions of mutated primary splice-site binding are shown with the predicted amount of correctly spliced mRNA,
given as a percentage of binding of the common allele (in parentheses).
(Mohsen et al. 1998). Finally, an intron 4 acceptor site
mutation (arg) was identified in FB143 that converted
the conserved ag to gg. As with FB145, IVD sequences
could not be amplified from the cDNA of FB143, which
suggests that the IVD mRNA is also unstable in this cell
line.
Information Analysis of Splice Junction Mutations
Because missplicing related to mutations in IVD exons
was unexpected, we conducted information analysis on
the predicted effect of these and the splice junction mu-
tations, on the strength of the splicing signal, by using
the Scan program (from the Laboratory of Computa-
tional and Experimental Biology at the National Insti-
tutes of Health) (Rogan et al. 1998). An example of these
analyses is shown in figure 5, and results for all the
mutations are summarized in table 1. The 149GrC mu-
tation in FB118 and FB136 strengthens a cryptic accep-
tor site (7.3r9.8 bits) at position 153, nine nucleotides
downstream from the natural splice site (8.5 bits). The
strengthened cryptic acceptor overlaps the natural site
and apparently interferes with recognition and assembly
of the spliceosome at this site. The mechanism of exon
skipping for the CrT mutation at position 148 (FB834)
appears to be similar; however, the cryptic site at posi-
tion 153 is only marginally strengthened (7.3r7.5 bits).
The insertion of a guanine residue within a polyguanine
run in exon 8 of the IVD gene in FB136 does not alter
the Ri value of the adjacent donor site (9.2 bits) and
does not create a cryptic site, although it leads to the
accumulation of both normal and abnormally sized IVD
mRNA species in this cell line. Of the eight subclones
of amplified cDNA from this region analyzed, one con-
tained the single nucleotide insertion, one was deleted
of exon 8, and six were of normal sequence (fig. 3C and
3D). The abnormal IVD mRNA identified in FB102 re-
sults from a gra mutation, one nucleotide upstream of
exon 8, which inactivates the natural acceptor site for
intron 7 splicing (5.4r2.2 bits) and uses a pre-existing
5.6-bit cryptic site upstream of exon 8. The intron 4
splice-junction mutations in FB103 and FB145 weaken
the intron 4 donor site (9.2r1.9 and 7.9r0.3 bits,
respectively).
Polymorphic Tandem Repeat in Intron 1 of the IVD
Gene
While sequencing intron 1 from FB834, we noticed a
sequence variant 25 nucleotides downstream of exon 1,
which consisted of three tandem copies of a 20-bp se-
quence flanked by 5-bp direct repeats in half the sub-
clones from this region (fig. 6A). The remaining clones
had one copy of the repeat. The patient was heterozy-
gous at this locus, having inherited a single repeat from
his homozygous father and three repeats from his het-
erozygous mother (whose alleles had two and three re-
peats; data not shown).
To determine the frequency of the intron 1 repeats,
the flanking region of genomic DNA was amplified from
70 control fibroblasts (table 2). A representative PCR
analysis from four samples is shown in figure 6B. The
variable repeat sequence is polymorphic with a hetero-
zygosity value of 0.26. Additional sequence analysis of
subclones from FB834 reveals that the 148CrT muta-
tion is linked to the IVD allele with three repeats in
intron 1 in the father and patient (not shown). To ex-
amine the effect of the intron 1 polymorphism on splic-
ing, exon-trapping vectors, consisting of normal exons
1–3 but with a variable number of intron 1 repeats, were
analyzed. Regardless of whether one, two, or three re-
peats were present, IVDmRNA produced from all three
vectors is correctly spliced in COS cells (data not shown).
Figure 5 Walker diagrams of IVD exon 2 splice acceptor sites. Splice sites are shown by walkers (Schneider 1997b), in which the height of each letter is the contribution of that base to the
total conservation of the site (in bits). The upper bound of the vertical rectangles is at 2 bits, and their lower bound is at 3 bits. Letters that are upside down represent negative contributions.
The top panel depicts the natural splice site one nucleotide upstream of exon 2 and a cryptic acceptor site at position 153. Neither cryptic site is used. The vertical arrows indicate the locations of
mutations in the sequence. The middle panel corresponds to the GrC change at position 149, and the lower panel to CrT at position 148. The mutations alter the Ri value of the cryptic acceptor
at position 153.
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Table 2
Frequency of Intron 1 Variable Repeats in
the IVD Gene
No. of Intron 1
Repeats
No. of Alleles
(Frequency)
1 17 (.12)
2 119 (.85)
3 4 (.03)
Figure 6 Polymorphic repeats in intron 1 of the IVD gene. A, Sequence of three, two, and one repeat alleles in intron 1, beginning 25
bp from the junction of exon 1 and intron 1. B, Amplification of intron 1 repeats from fibroblast cDNA. Fragments corresponding to each
number of repeats are shown.
Discussion
Mutations leading to missplicing and exon skipping
account for 15%–20% of mutations leading to human
disease (Krawczak et al. 1992). Thus, the high frequency
of splicing mutations in IVD in patients with IVA is
unusual (to date, 9 of 20 mutant alleles characterized;
this report and Mohsen et al. 1992). In addition, exon
skipping due to single-base mutations in exons has only
rarely been reported as a cause of human disease (Lig-
tenberg et al. 1991; Berg et al. 1992; Steingrimsdottir et
al. 1992; Li et al. 1995; Liu et al. 1997; O’Neill et al.
1998). A 2055CrT mutation in exon 8 of the ATP7A
gene encoding a Ser637Leu substitution leads to skip-
ping of exon 8 in splicing (Ronce et al. 1997). Several
single nucleotide substitutions in exons 3 and 8 of the
HPRT gene in patients with Lesch-Nyhan syndrome
have been identified, which lead to deletion of these ex-
ons in splicing (Steingrimsdottir et al. 1992; O’Neill et
al. 1998), whereas a similar effect on exon 2 has been
described with a single-base polymorphism of that exon
in the MUC1 gene (Ligtenberg et al. 1991). Single-base
changes in exons leading to exon skipping have been
described in patients with Laron dwarfism, Crouzon syn-
drome, and Marfan syndrome (Berg et al. 1992; Li et
al. 1995; Liu et al. 1997).
Exon substitutions may affect splicing by altering the
adjacent splice site, creating or activating secondary
splice sites, or concurrently mutating a splicing enhancer
element. Computer analysis reveals the presence of two
potential acceptor sites in the vicinity of the exon 2/
intron 1 boundary—the natural one and a cryptic one
about seven nucleotides downstream. Both sites are of
approximately equal strength and overlap considerably.
The 148CrT and 149GrC mutations do not signifi-
cantly alter the information content of the natural site
or activate secondary sites. Rather, the mutations appear
to prevent either site from being recognized appropri-
ately, leading to loss of definition of the exon and skip-
ping of this exon during splicing. Although we cannot
exclude the possibility that these changes may have a
corollary effect on a splicing enhancer sequence, it seems
more likely that these mutations represent another pre-
viously unrecognized class of splicing mutation.
The cause for missplicing related to the remaining
exon 2 mutation (205GrA) is not clear. No unusual
secondary structures are obvious in this region of the
IVD gene. The polymorphic repeat in intron 1 is inter-
esting but unlikely to be significant in relation to splicing,
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given our population data. In the case of the HPRT gene,
mutations in exon 8 have been postulated to affect sec-
ondary structure of the primary RNA transcript, perhaps
masking a splicing enhancer, and thus leading to mis-
splicing of exon 8 sequences (Steingrimsdottir et al.
1992; O’Neill et al. 1998). Overall, our findings are
consistent with the hypothesis that exon sequences can
play a crucial role in determining the integrity of the
splicing mechanism and guiding the processing of IVD
RNA. Moreover, the magnitude of the disruption of
exon 2 splicing appears to be related to the position of
the mutation within the exon, because the mutation at
position 148 leads predominantly to a product lacking
exon 2, whereas the 205GrA and 149GrC mutations
result in accumulation of both normal and abnormally
spliced products.
Insertion of a G residue at position 870 in exon 8
(FB136) (fig. 2C) leads to skipping of this exon. Because
most of the IVD subclones identified in these experi-
ments contain a normal sequence in this location, it is
conceivable that the misspliced RNA is less stable than
the wild type. The Scan program (from the Laboratory
of Computational and Experimental Biology at the Na-
tional Institutes of Health) does not predict a change in
the information content of the exon 8 donor site by this
mutation, so an alternative mechanism for missplicing
must be hypothesized. It has recently been shown that
RNA must form loops for different splicing factors to
interact with one another at splicing-enhancer sites
(Graveley et al. 1998). It is possible that the insertion
of another guanine residue into the poly-G tract already
present may lead to an alteration of secondary structure
that interferes with the splicing machinery, resulting in
the production of unstable message. Indeed, even a silent
nucleotide substitution has been shown to induce exon
skipping (Liu et al. 1997). Alternatively, frameshift mu-
tations and mutations creating a new stop codon have
elsewhere been suggested to lead to instability of the
nuclear RNA, perhaps related to a nuclear scanning
function or direct coupling of RNAprocessing and trans-
lation (Dietz et al. 1993; Dietz and Kendzior 1994).
In summary, we have identified an unusually high fre-
quency of splicing errors in IVDmRNA in patients with
IVA, including missplicing related to coding mutations.
The causative nature of these latter mutations has been
substantiated in a cellular-based model splicing system.
In general, stable mRNAs appear to be produced by
exon skipping if the resulting message maintains an open
frame (as shown for the exon 2 mutations), whereas
exon-skipping events that result in a frameshift (such as
the splicing mutations affecting exon 4, or the G inser-
tion in exon 8) either do not occur or produce unstable
RNA species. Additional analysis of splicing in this sys-
tem should prove helpful in further elucidating the nor-
mal mechanism of splicing of IVD mRNA.
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